Quick Answer: Tirzepatide burns fat primarily by reducing appetite and caloric intake through dual GIP and GLP-1 receptor activation, creating an energy deficit that promotes fat mobilization and oxidation
GLP-1 therapy has been shown to reduce markers of inflammation, which protects the heart and overall vascular system
Another update recommends considering glucagonlike peptide1 [GLP1] receptor agonists for highrisk patients with CVD who have type 2 diabetes, which is in line with the findings of recently published clinical trials, including the LEADER (ClinicalTrials.gov identifier: NCT01179048) trials 2
This included 28,430 cardiovascular deaths (NNT = 254), 83,489 nonfatal myocardial infarctions (NNT = 78), and 24,521 nonfatal strokes (NNT = 284)
The differences between our study and their study were that heart dilation and systolic dysfunction were present because of 16 weeks follow-up in their study
Use of GLP1RAs and occurrence of respiratory disorders: a meta-analysis of large randomized trials of GLP1RAs